4-bromo-1H-indazol-3-yl 2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranoside | 864845-16-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-bromo-1H-indazol-3-yl 2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranoside
• 英文别名: 4-bromo-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole；4-Bromo-3-(2,3,4,6-tetra-O-pivaloyl-beta-D-glucopyranosyloxy)-1H-indazole；[(2R,3R,4S,5R,6S)-6-[(4-bromo-1H-indazol-3-yl)oxy]-3,4,5-tris(2,2-dimethylpropanoyloxy)oxan-2-yl]methyl 2,2-dimethylpropanoate
• CAS: 864845-16-9
• 化学式: C₃₃H₄₇BrN₂O₁₀
• 分子量: 711.648
• InChiKey: ZZCZLUNKZZWVFA-HPWZOEIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  46
• 可旋转键数：
  15
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  152
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  4-bromo-1H-indazol-3-yl 2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranoside 在 palladium 10% on activated carbon 、 氢气 、 palladium diacetate 、 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 11.0h， 生成 4-(2-phenylethyl)-1H-indazol-3-yl 2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranoside
  参考文献：
  名称：

  发现 remogliflozin etabonate：一种有效且高度选择性的 SGLT2 抑制剂

  摘要：

  我们优化了口服给药后从小鼠尿液中获得的 WAY-123783活性代谢物(1)的结构，以提高对 SGLT2 的选择性和口服生物利用度。O-葡萄糖苷衍生物24（remogliflozin etabonate）随后被鉴定为一种有效的、高选择性的、可口服的 SGLT2 抑制剂。

  DOI：

  10.1016/j.bmc.2021.116033
• 作为产物：
  描述：

  2,3,4,6-O-四特戊酰基-alpha-D-溴代吡喃葡萄糖 、 4-溴-1,2-二氢-3H-吲唑-3-酮 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 以30%的产率得到4-bromo-1H-indazol-3-yl 2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranoside
  参考文献：
  名称：

  发现 remogliflozin etabonate：一种有效且高度选择性的 SGLT2 抑制剂

  摘要：

  我们优化了口服给药后从小鼠尿液中获得的 WAY-123783活性代谢物(1)的结构，以提高对 SGLT2 的选择性和口服生物利用度。O-葡萄糖苷衍生物24（remogliflozin etabonate）随后被鉴定为一种有效的、高选择性的、可口服的 SGLT2 抑制剂。

  DOI：

  10.1016/j.bmc.2021.116033

文献信息

• Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
  申请人：G.D. Searle & Co.

  公开号：US20040198989A1

  公开（公告）日：2004-10-07

  Selected heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

  选定的杂环羰基氨基酸羟乙基氨磺酰胺化合物可作为逆转录病毒蛋白酶抑制剂，特别是作为HIV蛋白酶的抑制剂。本发明涉及这种逆转录病毒蛋白酶抑制剂，更具体地涉及选定的新化合物、组合物和方法，用于抑制逆转录病毒蛋白酶，如人类免疫缺陷病毒（HIV）蛋白酶，预防逆转录病毒感染或逆转录病毒的传播，以及治疗逆转录病毒感染。
• Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
  申请人：G.D. Searle & Co.

  公开号：US20030191166A1

  公开（公告）日：2003-10-09

  Selected sulfonylalkanoylamino hydroxyethylamine sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

  选择的磺酰基烷酰胺基羟乙基磺酰胺化合物在逆转录病毒蛋白酶抑制剂方面具有良好的效果，特别是在HIV蛋白酶抑制剂方面。本发明涉及这种逆转录病毒蛋白酶抑制剂，更具体地涉及选择的新化合物、组合物和方法，用于抑制逆转录病毒蛋白酶，如人类免疫缺陷病毒（HIV）蛋白酶，预防逆转录病毒感染或逆转录病毒的传播，并治疗逆转录病毒感染。
• Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
  申请人：G. D. Searle & Co.

  公开号：US20040260095A1

  公开（公告）日：2004-12-23

  Selected amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

  选择的氨基醇基氨基磺酰胺化合物作为逆转录病毒蛋白酶抑制剂是有效的，特别是作为HIV蛋白酶的抑制剂。本发明涉及这种逆转录病毒蛋白酶抑制剂，更特别地涉及选择的新化合物、组合物和方法，用于抑制逆转录病毒蛋白酶，如人类免疫缺陷病毒（HIV）蛋白酶，预防逆转录病毒感染或逆转录病毒的传播，并治疗逆转录病毒感染。
• Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
  申请人：G.D. Searle & Co.

  公开号：US20030204097A1

  公开（公告）日：2003-10-30

  Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

  选定的双氨基酸羟乙基氨基磺酰胺化合物可作为逆转录病毒蛋白酶抑制剂，特别是作为HIV蛋白酶抑制剂。本发明涉及这种逆转录病毒蛋白酶抑制剂，更特别地，涉及选定的新化合物、组合物和方法，用于抑制逆转录病毒蛋白酶，如人类免疫缺陷病毒（HIV）蛋白酶，预防逆转录病毒感染或逆转录病毒的传播，并治疗逆转录病毒感染。
• NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS
  申请人：FUSHIMI Nobuhiko

  公开号：US20080188426A1

  公开（公告）日：2008-08-07

  The present invention provides nitrogen-containing fused-ring derivatives represented by the following general formula, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula R 1 represent H, an optionally substituted alkyl group, an alkenyl group, etc.; R 2 represent H, a halogen atom or an alkyl group; R 3 and R 4 represent H, OH, a halogen atom, an optionally substituted alkyl group, etc.; Y represents CH or N; Q represents alkylene, alkenylene, etc.; ring A represents an aryl group or a heteroaryl group; G represents a group represented by the following general formula (G-1) or (G-2) (in which E 1 represents H, F or OH; and E 2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

  本发明提供以下通式所表示的含氮融合环衍生物，或其药学上可接受的盐或前药，它们在人类SGLT中表现出优异的抑制活性，并可用作预防或治疗与高血糖相关的疾病，如糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症或肥胖症的药物。其中，通式中R1代表H，可选取代的烷基，烯基等；R2代表H，卤素原子或烷基；R3和R4代表H，OH，卤素原子，可选取代的烷基等；Y代表CH或N；Q代表烷基，烯基等；环A代表芳基或杂芳基；G代表下列通式（G-1）或（G-2）所表示的基团（其中E1代表H，F或OH；E2代表H，F，甲基基团等），以及包含它们的制药组合物和制药用途。